Searched for
ASTRA ZENECA
Medical device maker Zimmer Biomet to hire 500 employees in 3 years for tech centre in IndiaMedical device giant Zimmer Biomet is set to significantly expand its Indian footprint by hiring 500 professionals over three years for its...- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- India a major growth market for Celonis, says senior execThe Germany-based company said it already serves 260 global capability centres (GCCs) in India, counting companies such as Mercedes-Benz, H...
- Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI fundingSerum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fres...
- Moderna and other groups get $60 million to develop Ebola vaccineCEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will supp...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
- From diapers to drugs: How India's global corporate hubs are putting AI to workHeads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...
- UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weighLondon’s FTSE 100 edged lower as losses in energy majors and AstraZeneca weighed on the index amid thin holiday trading. Weak crude prices ...
- AstraZeneca plans to invest $405 million in Britain, PM Keir Starmer saysPrime Minister Keir Starmer announced AstraZeneca will invest 300 million pounds in UK life sciences. This significant investment secures 1...
- AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 croreThe land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...
- China probing AstraZeneca employees for potential illegal actsAstraZeneca has confirmed that several of its employees in China are under investigation for potential illegal data collection and unapprov...
- AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fightOn Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $1...
- AstraZeneca India Q1 results: Net profit declines 45% to Rs 10 crRevenue from operations stood at Rs 175.40 crore for the quarter under consideration. It was Rs 193.57 crore for the same period a year ago...
- AstraZeneca Pharma India appoints Gagan Singh Bedi as MDThe company has accepted resignation of Sanjay Murdeshwar as MD and as a director. He is shifting to a global role within the AstraZeneca g...
- AstraZeneca rejects 55 pounds/share Pfizer offerBritain's AstraZeneca on Monday rejected a sweetened 55-pounds-a-share offer from Pfizer.
- AstraZeneca Pharma board approves delisting of company's shares from stock exchangesAstraZeneca Pharma today said its board has approved delisting of the company's shares from bourses, including BSE and the National Stock E...
- AstraZeneca Pharma hits 52-week low as promoter likely to reduce stakeAstraZeneca slipped over 11% to hit its 52-week low on reports that its promoter has decided to reduce shareholding.
Load More
